10-Q: Progyny Q1 2026: Net Income Soars 61% Amidst Client Growth

Progyny, Inc. reports a significant 61% increase in net income for Q1 2026, driven by client expansion and improved gross margin, despite a modest 1% revenue growth.

Summary

• Net income for the three months ended March 31, 2026, increased by 61% to $24.2 million, up from $15.1 million in the prior year period.
• Revenue grew by 1% to $328.5 million for Q1 2026, compared to $324.0 million in Q1 2025, with both fertility and pharmacy benefits solutions contributing to the increase.
• Gross profit rose by 10% to $83.1 million, and gross margin expanded by 190 basis points to 25.3% for the quarter, attributed to efficiencies in care management services and reduced stock-based compensation.
• Operating expenses decreased by 8% overall, with sales and marketing down 5% and general and administrative down 9%, primarily due to lower stock-based compensation expense.
• The company served 595 clients and approximately 7.179 million members as of March 31, 2026, an increase from 555 clients and 6.689 million members as of December 31, 2025.
• Assisted Reproductive Treatment (ART) cycles decreased slightly to 15,647 in Q1 2026 from 16,160 in Q1 2025, influenced by the non-renewal of a large client in 2025.
• Member utilization rates for all fertility and family building services increased to 0.56% for all members and 0.48% for female-only members in Q1 2026.
• The $200 million share repurchase program authorized in November 2025 was completed as of March 31, 2026, with 5,511,824 shares repurchased at an average price of $21.13.
• Cash and cash equivalents increased to $131.6 million as of March 31, 2026, from $112.2 million at December 31, 2025, while marketable securities decreased to $93.5 million from $197.9 million.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive report, with strong profitability and margin expansion, despite modest revenue growth. The completion of the share repurchase program and continued client acquisition are favorable, though the slight decrease in ART cycles and Adjusted EBITDA warrant monitoring.

Positives

• Net income increased significantly by 61% to $24.2 million, demonstrating strong profitability growth.
• Gross profit increased by 10% and gross margin improved by 190 basis points to 25.3%, indicating enhanced operational efficiency.
• Operating expenses decreased across sales and marketing (5%) and general and administrative (9%), contributing to higher income from operations.
• Client base expanded to 595 clients and covered lives grew to 7.179 million, reflecting continued market penetration and growth.
• Member utilization rates for fertility and family building services showed an increase for both all members (0.56%) and female-only members (0.48%).
• The company maintains a strong liquidity position with $131.6 million in cash and cash equivalents and an undrawn $200 million revolving credit facility.
• The November 2025 share repurchase program was successfully completed, returning value to shareholders.

Negatives

• Revenue growth was modest at 1%, primarily offset by the impact of a large client who did not renew services in 2025.
• Adjusted EBITDA decreased by 2% to $56.6 million, despite the increase in net income, due to adjustments for non-cash items.
• Assisted Reproductive Treatment (ART) cycles decreased by 3.2% year-over-year, partly due to the non-renewal of a large client.
• Interest and other income, net, decreased by 36% to $1.5 million, primarily due to a decrease in interest income and an increase in interest expense.
• Marketable securities decreased significantly from $197.9 million to $93.5 million, indicating a shift in investment strategy or use of funds.

Risks

• Failure to meet publicly announced guidance or other expectations could cause stock price decline.
• Operating in a highly competitive market with more established competitors and potential new entrants.
• Unfavorable conditions in the global economy or industry, including inflation, interest rate fluctuations, and geopolitical conflicts, could limit business growth.
• Dependence on retaining existing clients and increasing adoption of services within the client base.
• Significant portion of revenue from largest clients and the technology industry, making the company vulnerable to changes in these areas.
• A significant change in the utilization of solutions, including consumption rate or mix, could adversely affect financial results.
• Operating in a highly regulated industry with evolving legal and regulatory requirements, including those related to reproductive rights, licensing, data privacy (HIPAA, CCPA), and PBM operations.
• Acquisitions, strategic investments, or partnerships could pose integration challenges, divert management attention, and dilute stockholder value.
• Limited operating history with current platform of solutions makes future results difficult to predict.
• Negative publicity in the health benefits industry could adversely affect business and financial condition.
• Information technology systems failures or cybersecurity breaches could disrupt services or lead to loss of confidential information.
• Use of artificial intelligence may subject the company to new or heightened legal, regulatory, ethical, or operational challenges.
• Dependence on maintaining the Center of Excellence network of high-quality fertility specialists and other healthcare providers.
• Growth depends on successful strategic relationships with channel partners, vendors, and insurance carriers.
• Failure to maintain an efficient pharmacy distribution network or disruptions to specialty pharmacies' supply chains or business economics.
• Potential inability to utilize net operating loss carryforwards due to ownership changes.
• Changes in effective tax rate or tax liabilities could adversely affect results of operations.
• State tax authorities may assert state nexus, leading to additional tax liabilities.
• Reported financial results may be adversely affected by changes in accounting principles.
• If estimates or judgments relating to critical accounting policies prove incorrect, results of operations could be adversely affected.
• Seasonality in revenue, with a higher proportion in the second half of the year, could create cash flow management risks.
• Failure to maintain and enhance the brand could impair ability to expand client base.
• Failure to retain management team or other key employees or attract additional qualified personnel.
• Litigation could be costly and time-consuming to defend and harm business.
• Exposure to credit risk from members for co-payments, co-insurance, and deductibles.
• Business with government entities is subject to specific challenges and risks.
• Failure to enforce intellectual property rights could impair ability to protect proprietary technology and brand.
• Anti-takeover provisions in charter documents and Delaware law could make an acquisition more difficult.
• Designation of Delaware courts as exclusive forum for certain actions could discourage lawsuits.

Future Outlook

Progyny expects costs and expenses to increase in future periods due to continued investment in sales and client success teams, expansion of new solutions and services for women's health and family building, and enhancement of technology infrastructure. The company issued guidance for Q2 2026 and full year 2026 on May 7, 2026, which is subject to various risks and uncertainties, including macroeconomic conditions and utilization trends. The company believes existing cash, marketable securities, and the revolving credit facility will be sufficient to support working capital and capital expenditure requirements for at least the next 12 months and long-term contractual obligations.

Management Comments

• We envision a world where everyone can realize their dreams of family and ideal health.
• Our mission is to empower healthier, supported journeys through transformative fertility, family building and women's health benefits.
• We have achieved this growth by demonstrating that our purpose-built, data-driven and disruptive platform consistently delivers superior clinical outcomes in a cost-efficient manner, while driving exceptional client and member satisfaction.
• We have retained substantially all of our clients since we launched our fertility benefits solution, and our member satisfaction is evidenced by our most recent industry-leading Net Promoter Score, or NPS, of +81 for our fertility benefits solution and +79 for Progyny Rx, our integrated pharmacy benefits solution, as of December 31, 2025.

Industry Context

StockSavvy.ai notes that Progyny operates in the rapidly evolving and competitive women's health and family building benefits sector. The company's continued client acquisition and expansion into broader women's health solutions (pregnancy, postpartum, menopause, benefit navigation, parent/child wellbeing) align with a broader industry trend of employers seeking comprehensive, integrated benefits to attract and retain talent. The slight decrease in ART cycles year-over-year, despite overall member growth, highlights the impact of specific client dynamics (like the non-renewal of a large client) on utilization metrics, which can mask underlying organic growth trends. The company's focus on a 'Center of Excellence' network and high NPS scores positions it favorably against competitors who may offer less integrated or lower-quality solutions, but the industry remains susceptible to economic downturns impacting employer benefits spending and increasing regulatory scrutiny on PBM practices.

Comparison to Industry Standards

• Progyny's in-network provider clinic averages for Progyny members only show a live birth rate per attempted retrieval of 46.7%, significantly higher than the national average of 34.9% (SART 2021, CDC 2022).
• The single embryo transfer rate for Progyny members is 96.6%, substantially above the national average of 78.9% (SART 2021).
• Progyny members experience a pregnancy rate per IVF transfer of 60.8%, exceeding the national average of 54.3% (SART 2021).
• The miscarriage rate for Progyny members is 14.4%, lower than the national average of 18.2% (SART 2021).
• Progyny's IVF multiples rate is 2.1%, considerably lower than the national average of 5.8% (CDC 2022), indicating safer and more effective treatment protocols.
• The company's Net Promoter Score (NPS) of +81 for its fertility benefits solution and +79 for Progyny Rx as of December 31, 2025, are industry-leading, demonstrating superior member satisfaction compared to typical healthcare benefit providers.

Legal Proceedings

• The company is not aware of any legal proceedings or claims that are believed to have a material adverse effect on its financial position or results of operations.

Stakeholder Impact

• Shareholders: Positive impact from increased net income, improved gross margin, and completion of share repurchase program, potentially leading to increased share value. However, modest revenue growth and decreased Adjusted EBITDA could temper enthusiasm.
• Employees: Continued investment in sales, client success, and technology infrastructure suggests ongoing growth and potential for new opportunities. Stock-based compensation remains a significant component of compensation.
• Customers (Clients): Benefit from expanded solutions in women's health and family building, high member satisfaction (NPS +81/+79), and superior clinical outcomes.
• Members: Continue to receive comprehensive fertility and family building benefits, access to a high-quality provider network, and dedicated care advocacy.
• Creditors: Strong liquidity position and compliance with financial covenants under the revolving credit facility indicate low credit risk.

Next Steps

• Continue to invest significantly in sales and marketing to drive new client acquisition and expand services within existing client base.
• Expand women's health and family building solutions to include pregnancy and postpartum, menopause and midlife, benefit and leave navigation, and parent and child wellbeing solutions.
• Continue to invest in enhancing technology infrastructure, including systems architecture, scalability, availability, performance, and security.
• Assess potential impacts to business and make adjustments to operations as necessary, particularly regarding evolving laws and regulations.
• Evaluate the impact of new accounting standards (ASU 2024-03, ASU 2025-06, ASU 2025-11) on consolidated financial statements and disclosures.

Key Dates

Recommendation

Progyny's Q1 2026 results show strong profitability growth and margin expansion, which are positive indicators. However, the modest 1% revenue growth and a slight decline in Adjusted EBITDA, coupled with a decrease in ART cycles, suggest that while the company is efficient, top-line expansion faces headwinds, partly from the non-renewal of a large client. The completion of the share repurchase program is a positive for shareholder returns. Given the mixed signals of strong bottom-line performance but slower revenue growth and some operational challenges (like ART cycle decline), a 'hold' recommendation is appropriate. Investors should monitor future revenue acceleration and the impact of new client acquisitions and expanded offerings on overall growth, alongside continued operational efficiency.

Keywords

Fertility Benefits, Family Building, Women's Health, Pharmacy Benefits Management, PBM, Smart Cycles, SEC Filing, 10-Q, Healthcare Benefits, Corporate Wellness, Employee Benefits, Progyny Rx, Assisted Reproductive Technology, ART, Net Promoter Score, NPS, Share Repurchase, Financial Results